
Brinzolamide



 $C_{12}H_{21}N_3O_5S_3$

383.51

- 2H-Thieno[3,2-*e*]-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (*R*)-; (*R*)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2Hthieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide
- [138890-62-7].

DEFINITION

Brinzolamide contains NLT 98.0% and NMT 102.0% of brinzolamide ($C_{12}H_{21}N_3O_5S_3$), calculated on the dried basis.

IDENTIFICATION

A. INFRARED ABSORPTION $\langle 197K \rangle$

• **B.** The retention time of the major peak of the Sample solution corresponds to that of the System suitability solution, as obtained in Limit of Brinzolamide Related Compound A.

ASSAY

PROCEDURE

- Buffer: Add 4.0 mL of triethylamine to 1000 mL of water, and adjust with phosphoric acid to a pH of 3.0. Mobile phase: Acetonitrile and Buffer (25:75)
- Standard solution: 0.1 mg/mL of USP Brinzolamide RS in Mobile phase

Sample solution: 0.1 mg/mL of Brinzolamide in Mobile phase

Chromatographic system

(See Chromatography (621), System Suitability.) Mode: LC

Detector: UV 254 nm Column: 4.6-mm × 25-cm; 5-μm packing L1

Flow rate: 1.0 mL/min

Injection volume: 20 µL System suitability

Sample: Standard solution

Suitability requirements

Column efficiency: NLT 1200 theoretical plates Tailing factor: NMT 2.0 Relative standard deviation: NMT 2.0%

Analysis

Samples: Standard solution and Sample solution Calculate the percentage of brinzolamide

 $(C_{12}H_{21}N_3O_5S_3)$ in the portion of Brinzolamide taken:

Result =
$$(r_U/r_S) \times (C_S/C_U) \times 100$$

- = peak response from the Sample solution r_U
- = peak response from the Standard solution rs = concentration of USP Brinzolamide RS in the Ċs
- Standard solution (mg/mL) Cu = concentration of Brinzolamide in the Sample

solution (mg/mL) Acceptance criteria: 98.0%–102.0% on the dried basis

IMPURITIES

Residue on Ignition (281): NMT 0.1%

Delete the following:

• HEAVY METALS, Method II (231): NMT 20 ppm (Official 1-

Change to read:

LIMIT OF BRINZOLAMIDE RELATED COMPOUND A Mobile phase: Dehydrated alcohol, Achromatographic hexane, *LUSP38* methanol, and diethylamine (55: 40: 5: 0.2) System suitability solution: 0.4 mg/mL of USP Brinzol-amide RS and 0.02 mg/mL of USP Brinzolamide Related Compound A RS in dehydrated alcohol Sample solution: 0.5 mg/mL of Brinzolamide in dehydrated alcohol Chromatographic system (See Chromatography (621), System Suitability.) Mode: LC Detector: UV 254 nm Column: 4.6-mm × 25-cm; packing L51 Flow rate: 0.75 mL/min Injection volume: 5 µL System suitability Sample: System suitability solution [Note—The relative retention times for brinzolamide and brinzolamide related compound A are 1.0 and 1.2, respectively.] Suitability requirements Resolution: NLT 1.8 between brinzolamide and brinzolamide related compound A peaks Column efficiency: NLT 2000 theoretical plates for the brinzolamide peak **Tailing factor:** NMT 1.8 for the brinzolamide peak Analysis **Sample:** Sample solution Calculate the percentage of brinzolamide related compound A in the portion of Brinzolamide taken: Result = $(r_U/r_T) \times 100$ = peak response for brinzolamide related rυ compound A = sum of the peak responses for brinzolamide rт and brinzolamide related compound A Acceptance criteria: NMT 0.5% **ORGANIC IMPURITIES** Buffer: Prepare as directed in the Assay. Mobile phase A: Prepare as directed for Mobile phase in the Assay. Mobile phase B: Acetonitrile and Buffer (35:65) System suitability solution: 0.1 mg/mL each of USP Brinzolamide RS and USP Brinzolamide Related Compound B RS in Mobile phase A Sample solution: 1 mg/mL of Brinzolamide in Mobile phase A Chromatographic system (See Chromatography (621), System Suitability.) Mode: LC Detector: UV 230 nm **Column:** 4.6-mm × 25-cm; 5-μm packing L1 Flow rate: 1.0 mL/min Injection volume: 10 μL System suitability Sample: System suitability solution Use Mobile phase A. [NOTE—The relative retention times for brinzolamide related compound B and brinzolamide are 0.8 and 1.0, respectively.] Suitability requirements Resolution: NLT 2.0 between the brinzolamide and brinzolamide related compound B peaks Column efficiency: NLT 1200 theoretical plates for the brinzolamide peak Tailing factor: NMT 2.0 for the brinzolamide peak Analysis 1 Use Mobile phase A.

Sample: Sample solution

- Allow the elution to continue for 20 min, and measure the areas for all the peaks, excluding the peaks of Mobile phase A.
- Calculate the percentage of each impurity in the portion of Brinzolamide taken:

Result =
$$(r_U/r_T) \times 100$$

= peak response for each impurity r_U

 r_{τ} = sum of all the peak responses Acceptance criteria 1: NMT 0.3% for any individual impurity

Analysis 2

Use Mobile phase B.

- Sample: Sample solution Allow the elution to continue for 20 min, and measure the areas for brinzolamide and all the peaks having a relative retention greater than 6.
- Calculate the percentage of each impurity in the portion of Brinzolamide taken:

Result =
$$(r_U/r_T) \times 100$$

= peak response for each impurity r_U

- r_{τ} = sum of all the peak responses Acceptance criteria 2: NMT 0.3% for any individual impurity; NMT 1.0% for total impurities from Analysis 1 and Analysis 2

SPECIFIC TESTS

• Loss on Drying (731) Analysis: Dry under vacuum at 100°–105° for 3 h. Acceptance criteria: NMT 0.5%

ADDITIONAL REQUIREMENTS

- PACKAGING AND STORAGE: Preserve in well-closed containers.
- **USP REFERENCE STANDARDS** $\langle 11 \rangle$ USP Brinzolamide RS
 - USP Brinzolamide Related Compound A RS
 - Brinzolamide (S)-isomer. $C_{12}H_{21}N_3O_5S_3$ 383.52

 - USP Brinzolamide Related Compound B RS (R-4-Amino)-2,3-dihydro-2-(3-methoxypropyl)-4H-thieno
 - [3,2,-e]-thiazine-6-sulfonamide-1,1-dioxide ethandioate 1.1 $C_{10}H_{17}N_{3}O_{5}S_{3}\cdot C_{2}H_{2}O_{4}$ 445.49

Brinzolamide Ophthalmic Suspension

DEFINITION

USP Monographs

Brinzolamide Ophthalmic Suspension is a sterile, aqueous suspension of Brinzolamide containing a suitable antimicrobial preservative. It contains NLT 90.0% and NMT 110.0% of the labeled amount of brinzolamide $(C_{12}H_{21}N_{3}O_{5}S_{3}).$

IDENTIFICATION

A. The retention time of the major peak of the Sample solution corresponds to that of Standard solution A, as obtained in the Assay.

ASSAY

Change to read:

- PROCEDURE
 - 11.75 g/L of ammonium acetate in water. Ad-Buffer: just with acetic acid to a pH of 5.2.

Mobile phase: Methanol and Buffer (35:65) Standard solution A: 0.2 mg/mL of USP Brinzolamide RS in Mobile phase System suitability solution: 0.06 mg/mL of USP Brinzolamide Related Compound B RS in Standard solution Sample solution: Nominally 0.2 mg/mL of brinzolamide in *Mobile phase* prepared as follows. Transfer a volume of Ophthalmic Suspension, equivalent to 10 mg of brinzolamide, into a 50-mL volumetric flask, and dilute with Mobile phase to volume. Chromatographić system (See Chromatography (621), System Suitability.) Mode: LC **Detector:** UV 254 nm **Column:** 4.6-mm × 15-cm; 5-µm packing L1 Flow rate: 1.0 mL/min Injection volume: 20 µL System suitability Samples: Standard solution A and System suitability solution [NOTE—The relative retention times for brinzolamide related compound B are between 0.48 and 0.61, and the relative retention time for brinzolamide is 1.0.] Suitability requirements **Resolution:** NLT 4.5 between the brinzolamide and brinzolamide related compound B peaks, *System suit*ability solution **Tailing factor:** NMT 2.0, System suitability solution Relative standard deviation: NMT 2.0%, Standard solution A Analysis Samples: Standard solution A and Sample solution Calculate the percentage of the labeled amount of brinzolamide $(C_{12}H_{21}N_3O_5S_3)$ in the portion of Ophthalmic Suspension taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

- = peak response from the Sample solution r_U
- = peak response from *Standard* solution A = concentration of USP Brinzolamide RS in rs Cs Standard solution A (mg/mL)
- = nominal concentration of brinzolamide in the Cu Sample solution (mg/mL)
- Acceptance criteria: 90.0%–110.0%

IMPURITIES

Change to read:

LIMIT OF BRINZOLAMIDE RELATED COMPOUND A Mobile phase: Dehydrated alcohol, Achromatographic hexane, *LUSP38* methanol, and diethylamine (55: 40: 5: 0.2) System suitability solution: 0.4 mg/mL of USP Brinzolamide RS and 0.02 mg/mL of USP Brinzolamide Related Compound A RS in dehydrated alcohol Sample solution: Transfer a volume of Ophthalmic Suspension, equivalent to 10 mg of brinzolamide, to a 25-mL volumetric flask. Dilute with alcohol to volume. Chromatographic system (See Chromatography (621), System Suitability.) Mode: LC Detector: UV 254 nm Column: 4.6-mm × 25-cm; packing L51 Flow rate: 0.75 mL/min **Injection volume:** 5 µL System suitability Sample: System suitability solution [NOTE—The relative retention times for brinzolamide and brinzolamide related compound A are 1.0 and